Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

(2013) Mauro Zukin et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study

(2012) Lihui Zhao et al.   Clinical Trials

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

(2012) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

The Hazards of Hazard Ratios

(2009) Miguel A. Hernán   EPIDEMIOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY